HomeCompareSLGD vs PFE

SLGD vs PFE: Dividend Comparison 2026

SLGD yields 160.00% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SLGD wins by $34.81M in total portfolio value
10 years
SLGD
SLGD
● Live price
160.00%
Share price
$1.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.86M
Annual income
$15,634,271.53
Full SLGD calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SLGD vs PFE

📍 SLGD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSLGDPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SLGD + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SLGD pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SLGD
Annual income on $10K today (after 15% tax)
$13,600.00/yr
After 10yr DRIP, annual income (after tax)
$13,289,130.80/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, SLGD beats the other by $13,266,810.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SLGD + PFE for your $10,000?

SLGD: 50%PFE: 50%
100% PFE50/50100% SLGD
Portfolio after 10yr
$17.45M
Annual income
$7,830,265.12/yr
Blended yield
44.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SLGD
No analyst data
Altman Z
0.5
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SLGD buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSLGDPFE
Forward yield160.00%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$34.86M$49.6K
Annual income after 10y$15,634,271.53$26,258.71
Total dividends collected$32.40M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SLGD vs PFE ($10,000, DRIP)

YearSLGD PortfolioSLGD Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$26,700$16,000.00$9,153$693.39+$17.5KSLGD
2$68,494$39,925.23$8,593$849.25+$59.9KSLGD
3$169,010$95,720.83$8,336$1,066.78+$160.7KSLGD
4$401,580$220,739.56$8,437$1,384.80+$393.1KSLGD
5$919,872$490,181.40$9,013$1,875.40+$910.9KSLGD
6$2,033,632$1,049,369.50$10,306$2,680.72+$2.02MSLGD
7$4,344,139$2,168,152.23$12,820$4,101.38+$4.33MSLGD
8$8,976,727$4,328,498.22$17,673$6,826.70+$8.96MSLGD
9$17,964,357$8,359,258.83$27,543$12,591.86+$17.94MSLGD
10$34,856,133$15,634,271.53$49,560$26,258.71+$34.81MSLGD

SLGD vs PFE: Complete Analysis 2026

SLGDStock

Scott's Liquid Gold-Inc., together its subsidiaries, develops, markets, and sells household, and health and beauty care products in the United States. It operates in two segments, Household Products, and Health and Beauty Care Products. The Household Products segment offers wood care and floor restore products under the Scott's Liquid Gold name; stain and odor removing products under the Kids N Pets and Messy Pet brand name for children and pets; and laundry care products under the Biz brand name. The Health and Beauty Care Products segment provides skin care products under the Alpha brand; and hair care products under the Prell and Denorex brands. It sells its products through sales force and independent distributors to mass merchandisers, drugstores, supermarkets, hardware stores, e-commerce retailers, and other retail outlets, as well as to wholesale distributors. Scott's Liquid Gold-Inc. was founded in 1951 and is headquartered in Greenwood Village, Colorado.

Full SLGD Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SLGD vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SLGD vs SCHDSLGD vs JEPISLGD vs OSLGD vs KOSLGD vs MAINSLGD vs JNJSLGD vs MRKSLGD vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.